Aiwell Inc.

Based in Japan, Aiwell Inc. specializes in developing innovative proteomics technologies, offering advanced solutions for comprehensive protein analysis in healthcare and wellness sectors. Aiwell Inc. is a company dedicated to proteomics technology applications, founded in Tokyo, Japan in 2018.

It has completed 7 deals, with the most recent deal occurring on December 11, 2023, during its Series A funding round, which raised JPY 42. 000 mn. The investment was led by Oisix ra daichi, and the total amount raised to date amounts to JPY 42. 000 mn, with a current company valuation of JPY 1310.

839 mn. Aiwell Inc. specializes in the development and application of proteomics technologies, which facilitate comprehensive protein analysis for various sectors. Their core product, aiwell care, is a home-based blood testing kit that offers high-precision results comparable to those obtained in clinical settings.

Unlike traditional micro-sampling methods that typically allow for approximately 15 tests, aiwell care can measure up to 45 parameters simultaneously, enabling users to conduct extensive health monitoring from home. This product is particularly aimed at early detection and management of diseases and injuries, catering to individual consumers who prioritize health and wellness as well as healthcare providers looking for efficient diagnostic solutions. The company's offerings are currently positioned within the Japanese market, with a focus on enhancing healthcare accessibility and supporting medical professionals and researchers. Aiwell Inc.

generates revenue through direct sales of their flagship product, aiwell care, which is marketed to both individual consumers and healthcare institutions. The transaction structure primarily involves B2C sales, where customers purchase the testing kits for personal use, alongside potential B2B partnerships with healthcare providers for bulk orders and collaborative research projects. Specific pricing plans are structured to accommodate both retail and wholesale orders, facilitating broader access to their products. By leveraging the capabilities of their proteomics technology, Aiwell aims to establish long-term relationships with medical professionals and institutions that prioritize advanced diagnostic methods, thus positioning themselves as a key player in the evolving landscape of health technology and diagnostics.

In December 2023, Aiwell Inc. raised an undisclosed amount in venture funding from Contrail LLC to invest in equipment and personnel recruitment for its research institute. The company aims to expand its product line, focusing on new offerings designed for health monitoring, with specific launch dates to be determined. Additionally, Aiwell plans to enter new markets beyond Japan, targeting regions in Asia by the end of 2024, to broaden its market reach and enhance healthcare solutions.